前沿生物：跨国药企合作最关注战略协同性、资产本身的差异化优势与研发进度

Group 1 - The core focus of multinational pharmaceutical collaborations is strategic alignment, specifically whether the disease area of the collaborative asset can effectively complement the existing pipeline [2] - The differentiation advantages and research progress of the asset itself are crucial, with solid research data, significant differentiation features, and industry-leading research advancement pace being key considerations [2] - GSK possesses a highly specialized research team with advanced advantages in relevant fields, which is highly valued by the company, reflecting GSK's capabilities in biomedical research, global clinical development, commercialization layout, and global resource integration [2]